WELCOME TO THE SULMAN LAB

Our laboratory studies the biology of brain tumors. These include some of the most lethal cancers, most notably glioblastoma, the most common and most aggressive primary malignant brain tumor in adults. In the lab, we study glioma stem cells which are responsible for tumor initiation and treatment resistance. We investigate molecular subtypes of gliomas and how they interact with tumor microenvironment which leads to treatment resistance. To optimize treatment for patients, the lab also develops novel molecular biomarkers of treatment response and patient outcome.  

The lab also focuses on developing new therapies for patients. We have developed a unique platform to characterize responses to new treatments, both alone and in combination. This approach allows us to capitalize on the >80 patient-derived tumor models we have in the lab by pooling DNA barcoded models together in high-throughput experiments both in vitro and in vivo. We especially focus on treatments that will improve the effectiveness of radiation therapy, one of the mainstay treatments for the majority of patients with brain tumors.  Using CRISPR screens, we also work to identify new targets for treatment based on their role in treatment resistance or tumor aggressiveness.

The laboratory receives funding from the NCI as well as multiple foundations, including the National Brain Tumor Society, through its DNA Damage Response Consortium (DDR-C), and previously from the American Brain Tumor Association.

Everything we do in the lab is focused on improving the outcome and quality of life for patients suffering from a diagnosis of a brain tumor. It is this focus that motivates all of us to perform the work we do.

IF YOU ARE INTERESTED IN A POST-DOCTORAL OR OTHER RESEARCH POSITION IN THE LAB, PLEASE CONTACT US.